ReviewMolecular medicine reports2026
Lactylation in gastric cancer: From mechanisms to clinical applications (Review).
Review in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) is one of the most common malignant tumors worldwide. Metabolic reprogramming and epigenetic dysregulation represent its key pathological characteristics. As a novel lactate‑mediated post‑translational modification, lactylation converts metabolic signals into epigenetic and protein functional regulation, and it is extensively and aberrantly activated in GC. Lactylation drives the malignant progression of GC by promoting cell proliferation, invasion, metastasis and stemness. In addition, lactylation suppresses antitumor immune cell functions, and mediates immune escape and therapeutic resistance. Clinically, global lactylation levels and specific lactylation sites can serve as independent prognostic biomarkers, and corresponding risk models enable prognostic stratification and prediction of immunotherapy response. Intervention strategies targeting lactate production, lactyltransferases and downstream effector axes have emerged as promising directions for GC treatment. The present review summarizes the regulatory mechanisms, biological functions and clinical translational value of lactylation in GC, aiming to provide novel insights for precision diagnostics and therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.